Deliver Consulting Limited | Back to main site
More

Program Overview

China and Asia over the decades has been playing an increasingly important role in the context of clinical research activities due to the significant scientific investment by multinational companies as well as rapidly booming China domestic R&D programs. In past few years, the China regulatory agency has also issued several regulations and initiatives to accelerate the review and approval and improve the quality of new drugs and medical devices. With the joining of ICH in 2017, the government is continuing to improve the regulatory standards and systems to promote innovation, enhance the R&D ecosystem. However, the drug development is fraught with all kinds of challenges which needs innovation, efficiency and collaboration. In return, the Clinical Development and Innovation Forum will gather leaders and scientists across pharma, biotech and academia for discussions and cases studies on the major topics including: Robust Clinical and Regulatory Strategy, Next Generation Clinical Trials, Oncology and Immuno-Oncology Drug Development, Clinical Biomarkers and Companion Diagnostics, Cellular Immunotherapy and Gene Therapy Development, Rare Diseases, Data Science and Digital Innovation, China Domestic R&D Innovation, Innovative Clinical Design and Patient Strategies towards the Efficient and GCP-compliant Drug Development in the era of Precision Medicine.

More

2022 Speaker Committee

  • Hongjun Yang

    Founder and Co-Director, The Committee of Precision Medicine
    Chinese Society of Biotechnology

    More>

  • Simon Li

    Chief Medical Officer
    Evive Biotech

    More>

  • Junyuan Wang

    Co-Founder
    AnHeart Therapeutics

    More>

  • Rong Chen

    Vice President of Biocytogen
    Chief Medical Officer, Eucure Biopharma

    More>

  • Gary Tong

    Co-Founder and CMO
    NeuroFront Therapeutics

    More>

  • Liandong Ma

    Vice President and President of R&D
    Kintor Pharmaceuticals

    More>

  • Ye Hua

    Founder and CEO
    BioNova Pharmaceuticals

    More>

  • Yukun Wang

    Head of Translational Medicine Oncology China
    Bayer Healthcare

    More>

More

Program Key Discussions

Session 1: Clinical and Regulatory Strategy, Next Generation Clinical Trials
Session 2: Oncology and Immuno-Oncology Drug Development
Session 3: Cellular Immunotherapy, Gene Therapy, Oncolytic Virus Immunotherapy Development
Session 4: Neurodegenerative Diseases, AutoImmune Diseases and Anti-Viral Therapy Development
Session 5: Biomarkers, Companion Diagnostics and Translational Medicine
Session 6: Biotherapeutics, Bispecific Antibodies and ADC 
Session 7: China Domestic New Drug Development and Translational Research
Sesison 8: Innovative Clinical Design and Biostatistics
Session 9: Early and Exploratory Drug Development Strategies
Session 10: Clinical Operation Excellence, Digital Innovation, Virtual Trials, AI and Big Data

More

Who would Attend

Approx. 600 senior R&D, Clinical and Translational, Medical and Regulatory executives and scientists are expected to attend the Clinical Development and Innovation Forum 2022. The participants will mainly come from the Pharma/Biotech, Academia, Investigational Sites, Regulatory Agencies, CROs, Central Labs, Technology and Service providers with the main responsibilities including:

- Corporate Executives and Head of R&D
- Clinical and Regulatory Strategy
- Medical Sciences and Affairs
- Biomarkers, Companion Diagnostics and Translational Medicine
- Clinical Innovation and Strategy
- Clinical Data Sciences and Biostatistics
- Clinical Operation and Quality Management
- Clinical Procurement and Sourcing
- Principal Investigators